The attempt to validate a score for stratifying the risk for new-onset T2DM is an important issue and, in this regard, Water and Coll. [34,39], on the basis of the above-mentioned TNT, IDEAL and SPARCL trials, proposed the following four main predictors upon statin treatment: fasting plasma glucose (FPG) N100 mg/dl, triglycerides N 150 mg/dl, body mass index N 30 kg/m2 and history of hypertension, thus producing a score ranging from 0 to 4 (Table 1)